Rexxolide RSS Authorised This medicine is authorised for use in the European Union tulathromycin Medicine Veterinary Authorised
Page contentsPage contents Overview Product information Product details Authorisation details Assessment history News on Rexxolide Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Rexxolide : EPAR - Medicine overviewReference Number: EMA/555704/2020 English (EN) (81.94 KB - PDF)First published: 12/03/2021 Last updated: 14/10/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View español (ES) (81.97 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View čeština (CS) (93.99 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View dansk (DA) (83.34 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View français (FR) (82.44 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View íslenska (IS) (83.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View italiano (IT) (82.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View magyar (HU) (94.15 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Malti (MT) (95.95 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View norsk (NO) (82 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View polski (PL) (95.62 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View português (PT) (83.01 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View română (RO) (94.17 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Suomi (FI) (81.54 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View svenska (SV) (82.05 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Product information Rexxolide : EPAR - Product information English (EN) (81.49 KB - PDF)First published: 12/03/2021 Last updated: 14/10/2025 View Other languages (25) български (BG) (91.78 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View español (ES) (81.51 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View čeština (CS) (92.48 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View dansk (DA) (82.05 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Deutsch (DE) (81.72 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View eesti keel (ET) (81.22 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View ελληνικά (EL) (91.79 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View français (FR) (81.63 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View hrvatski (HR) (91.56 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View íslenska (IS) (81.52 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Gaeilge (GA) (81.36 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View italiano (IT) (81.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View latviešu valoda (LV) (92.14 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View lietuvių kalba (LT) (92.19 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View magyar (HU) (92.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Malti (MT) (93.86 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Nederlands (NL) (81.15 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View norsk (NO) (81.52 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View polski (PL) (93.22 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View português (PT) (82.53 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View română (RO) (91.73 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenčina (SK) (81.75 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenščina (SL) (81.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Suomi (FI) (81.11 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View svenska (SV) (81.47 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Rexxolide : EPAR - All authorised presentations English (EN) (81.94 KB - PDF)First published: 12/03/2021 Last updated: 14/10/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View español (ES) (81.97 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View čeština (CS) (93.99 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View dansk (DA) (83.34 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View français (FR) (82.44 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View íslenska (IS) (83.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View italiano (IT) (82.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View magyar (HU) (94.15 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Malti (MT) (95.95 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View norsk (NO) (82 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View polski (PL) (95.62 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View português (PT) (83.01 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View română (RO) (94.17 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Suomi (FI) (81.54 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View svenska (SV) (82.05 KB - PDF) First published: 12/03/2021 Last updated: 14/10/2025 View Product details Name of medicine Rexxolide Active substance tulathromycin International non-proprietary name (INN) or common name tulathromycin Pharmacotherapeutic groupAntibacterials for systemic use Authorisation details EMA product number EMEA/V/C/005384 Assessment history Expand section Collapse section Changes since initial authorisation of medicine Rexxolide : EPAR - Procedural steps taken and scientific information after authorisation English (EN) (81.94 KB - PDF)First published: 03/08/2021 Last updated: 14/10/2025 View Initial marketing authorisation documents Rexxolide : EPAR - Public assessment reportAdopted Reference Number: EMA/557847/2020 English (EN) (81.49 KB - PDF)First published: 12/03/2021 Last updated: 14/10/2025 View CVMP summary of positive opinion for RexxolideAdopted Reference Number: EMA/CVMP/496850/2020 English (EN) (65.72 KB - PDF)First published: 09/10/2020 View News on Rexxolide Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 November 202408/11/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-17 January 202419/01/2024 Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 6-7 October 202009/10/2020 This page was last updated on 14/10/2025 Share this page